EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours

Allison M Weisnicht iD, Fernanda Szewc, Monica Moonkyung Cho, Han-Yun Hannah Cheng iD, Swetha Ganesh, Lauren Mahoney iD, Kathryn Fox iD, Portia R Smith, Mallery Olsen iD, Rebecca M Richards iD, David M Vail iD, Christian M Capitini iD

Veterinary and Comparative Oncology · 2026-12 · 24 (4) · 745-755

DOI: 10.1111/vco.70091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, online erschienen am 16.07.2026. Verfasst von Allison M Weisnicht und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Killer Cells, Natural, Dog Diseases, Osteosarcoma, Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: St. Baldrick's Foundation, NCATS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Companion canines need advances in therapeutic options for solid tumour malignancies. Natural killer (NK) cell infusions offer a promising treatment modality in canines with solid tumours. Autologous natural killer products are limited by dysfunctional immunity and a manufacturing process that delays care whereas allogeneic NK cells offer the possibility of ‘off‐the‐shelf’ therapy to be administered from healthy donors. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy canine donors via density gradient separation. NK cells were expanded with recombinant human IL‐2 and canine IL‐21 with the addition of K562 feeder cells transfected with CD137 ligand and membrane bound human IL‐15. Additional experiments included IL‐12 during expansion. In vitro potency was assessed via co‐culture with the D17‐mKate2 canine osteosarcoma cell line. Three canines were enrolled in a phase 1 trial infusing ex vivo expanded allogeneic NK cells after lymphodepletion. Flow cytometric analysis confirmed successful expansion of canine NK cells with up to 50% of cells demonstrating NKp46+ after 14 days. Residual T cell numbers varied based on donor. The addition of IL‐12 led to increased NK cell expansion. Incucyte demonstrated potency with increasing osteosarcoma cell death at higher effector to target ratios. Three canines with metastatic/refractory solid tumours were successfully lymphodepleted and infused with allogeneic NK cell products. The canines tolerated the infusions well. Canine allogeneic NK cells were successfully expanded and activated ex vivo, demonstrated potency in vitro and safety in vivo. Further studies will optimise the NK cell product and escalate dosing to reach the maximal tolerable dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalDog DiseasesOsteosarcomaNeoplasmsAnimalsDogsFemaleCell Line, TumorMaleNeoplasm Metastasis

Stichwörter der Autor:innen

IL‐12NK cellsallogeneiccanineclinical trialosteosarcoma

Autor:innen und Institutionen

  • Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
  • Department of Medical Sciences, University of Wisconsin School of Veterinary Medicine, Madison, Wisconsin, USA.
  • Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
  • Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: Allison M Weisnicht, Han-Yun Hannah Cheng, Lauren Mahoney, Kathryn Fox, Mallery Olsen, Rebecca M Richards, David M Vail, Christian M Capitini

Förderung

  • St. Baldrick's Foundation
  • NCATS NIH HHS
  • NCI NIH HHS
  • NIGMS NIH HHS
  • Lion's Club International
  • NIH HHS
  • NHLBI NIH HHS
  • Midwest Athletes Against Childhood Cancer

Zitieren

APA

Weisnicht, A. M., Szewc, F., Cho, M. M., Cheng, H. H., Ganesh, S., Mahoney, L., Fox, K., Smith, P. R., Olsen, M., Richards, R. M., Vail, D. M., & Capitini, C. M. (2026). Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours. Veterinary and Comparative Oncology, 24(4), 745-755. https://doi.org/10.1111/vco.70091

Vancouver

Weisnicht AM, Szewc F, Cho MM, Cheng HH, Ganesh S, Mahoney L, et al. Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours. Veterinary and Comparative Oncology. 2026;24(4):745-755. doi:10.1111/vco.70091

BibTeX
@article{Weisnicht2026,
  author = {Weisnicht, Allison M and Szewc, Fernanda and Cho, Monica Moonkyung and Cheng, Han-Yun Hannah and Ganesh, Swetha and Mahoney, Lauren and Fox, Kathryn and Smith, Portia R and Olsen, Mallery and Richards, Rebecca M and Vail, David M and Capitini, Christian M},
  title = {Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours},
  journal = {Veterinary and Comparative Oncology},
  year = {2026},
  volume = {24},
  number = {4},
  pages = {745--755},
  doi = {10.1111/vco.70091}
}
Kostenlos starten →